Clinical Trial

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

Study acronym: SYNOVIIIUS
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-16; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-10-28
Trial Details
NCT Number NCT06941870
Lead Sponsor Sanofi
Conditions Factor VIII Deficiency
Enrollment 35 participants
Start Date 2025-09-23
Primary Completion 2027-10-25 (estimated)
Study Completion 2027-10-25 (estimated)
Updated on ClinicalTrials.gov 2025-11-18